PSMA- PSMA-targeting radiopharmaceuticals for diagnosis and therapy of prostate cancer

摘要

The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer, which is capable of PSMA-target. According to the structure of the compound provided by an embodiment of the present invention, chelator combined with radioactive metal is combined in a glutamine-urea-lysine compound and an aryl group is combined to be able to have an additional binding with PSMA protein. A bonding between the glutamine-urea-lysine compound and the chelator is formed in a polar spacer to reduce a nonspecific binding inside a living body, and has an effect of quickly removing the nonspecific binding from major organs besides prostate cancer. The feature of the present invention has advantages of lowering radiation exposure to normal tissues and organs caused by a compound bound to radioisotopes for treatment and thus, reducing side effects. In addition, the compound containing a phenyl group having a binding force to albumin has an effect of being accumulated more in prostate cancer by increasing residence time in blood.